DKK1 and prostate carcinoma: A phase 1b/IIa parallel-arm study of the DKK1 inhibitor DKN-01 as monotherapy or in combination with docetaxel in advanced prostate cancer with elevated DKK-1 is ongoing (NCT03837353).